Objective: To investigate the curative effect of Gishao capsule combined with irbesartan for the patients with diabetic nephropathy (DKD). Method: The 84 patients with DKD from January 2014 to April 2015 were enrolled into the study and randomly divided into observation group and control group

n=42 in both groups. Patients in the control group received irbesartan 150 mg qd. Based on it

patients in the observation group also received Gishao capsule

5 pills tid. The sugar metabolism index and renal index were compared between two groups before and after treatment. And the curative effect were also compared between two groups. Result: The fasting plasma glucose (FPG)

glycosylated hemoglobin (HbA1c) in the observation group were all significantly lower than the control group after treatment (P<0.05). Serum creatinine (SCr)

urinary albumin excretion rate (UAER)

24 h urine protein (24 hUP)

microalbuminuria (mALB)

ratio of microalbuminuria to creatinine (mALB/UCr) and blood urea nitrogen (BUN) in the observation group were (135.7±18.9) μmol·L-1

(155.3±28.1) mg·(24 h)-1

(1.53±0.44) g

(39.7±12.9) μg·L-1

(15.5±3.9) mg·g-1

(6.59±0.87) mmol·L-1 respectively

which were all significantly lower than (163.6±18.0) μmol·L-1

(170.6±32.3) mg·(24 h)-1

(1.79±0.52) g

(47.4±14.4) μg·L-1

(17.7±3.8) mg·g-1

(7.06±0.93) mmol·L-1 in the control group (P<0.05). The curative effect in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: Compared with irbesartan alone

Qishao capsule combined with irbesartan could improve the renal function of DKD patients more significantly

delay the progress of disease and have significant curative effect

which fully shows the unique advantage of Chinese with western medicine therapy and is worthy of clinical popularization and application.